US_Flag An official website of the United States government Here's how you know

The .gov means it's official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.


The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

U.S. Food & Drug Administration
Continuing Education and Accreditation
Division of Learning and Organizational Development
Center for Drug Evaluation and Research

Online Learning

Select the activity title to enroll in online learning activties. Learners must complete all educational content and the course evaluation to earn CE credit.


32 matches found
Title Type
FDA’s Role in Postmarketing Drug Safety Surveillance Enduring Material 
How FDA and ISMP Utilize Medication Error Reports to Improve Drug Safety Enduring Material 
Overview of Expanded Access (EA) Program and EA eRequest Site Enduring Material 
Biosimilar and Interchangeable Biosimilars: Review of Scientific Concepts, Case Studies, and Resources Enduring Material 
Fraudulent Products – Hidden Ingredients and Unproven Claims in Products Marketed as Dietary Supplements Enduring Material 
Enhanced Drug Distribution Security: 2023 and Beyond Enduring Material 
Safety Labeling Changes for Leukotriene Receptor Antagonists and Decisions Behind a Boxed Warning Enduring Material 
Project Facilitate: Oncology Expanded Access Program Update Enduring Material 
FDA’s Office of Orphan Products Development (OOPD) – An Overview and Update Enduring Material 
The Ins and Outs of Prescription Drug Labeling Enduring Material 
Orange Book: Frequently Asked Questions and Answers Enduring Material 
Counseling Patients on Generic Drugs Enduring Material 
Labeling Made Simple: The How, What, and Where of Drug Interactions in Prescribing Information Enduring Material 
An Overview of Naloxone and FDA’s Efforts to Expand Access Enduring Material 
Overview of Risk Evaluation and Mitigation Strategies (REMS) for Health Care Providers Enduring Material 
Pregnancy and Lactation Medication Information for the Healthcare Provider Enduring Material 
FDA Drug Information Resources and Applicability to Health Care Professionals Enduring Material 
Reporting and Public Viewing of Individual Case Safety Reports (ICSRs) Enduring Material 
Drug Shortages: Root Causes and Potential Solutions Enduring Material 
Engaging Providers to Address Knowledge Gaps on Medication Use in Pregnancy and Lactation -- Enduring Material Enduring Material 
Development and U.S. Regulation of Preventive Vaccines Enduring Material 
Understanding Generic Narrow Therapeutic Index Drugs Enduring Material 
The Safety Evaluation and Surveillance of Generic Drugs Enduring Material 
Frequently Asked Questions about Labeling for Prescription Medicines Enduring Material 
Assessment of Stromal Tumor-Infiltrating Lymphocytes Enduring Material 
PCOS Revisited: Diagnosis, Management, and Future Needs Enduring Material 
Rare Diseases - Challenges and Progress in Drug Development Enduring Material 
FDA Drug Topics: How to Avoid Medication Errors with Pen Injectors Enduring Material 
Q&A with FDA Podcast: Expanded Access with Dr. Jacqueline Corrigan-Curay Enduring Material 
Regulatory Framework for Human Drug Compounding Enduring Material 
Naltrexone Injection for Opioid Use Disorder - FDA’s Efforts to Reduce Medication Errors Enduring Material 
Q&A with FDA Podcast: A Step Forward in the Treatment of Opioid and Alcohol Dependence with Dr. Iilun Murphy and Dr. Marta Sokolowska Enduring Material 
Back To Top